## Voriconazole Voriole Patient Alert Card

Please carry this card with you at all times.

This card contains **important safety information** you need to be aware of before you are given Voriconazole for prevention of fungal infections, or during treatment with Voriconazole for your fungal infection.

If you do not understand this information, please ask your doctor or healthcare professional involved in your care to explain it to you.

Show this card to any doctor or healthcare professional involved in your care.

See the Voriconazole package leaflet for more information.



### Other Information (please complete):

# Name Date Voriconazole First Prescribed Treating Doctor's Name Treatment Centre Name Treatment Centre Phone Number

You should avoid exposure to direct sunlight during Voriconazole treatment. It is important to cover sun exposed areas of skin and use sufficient sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun's UV rays can occur. There is a small chance that skin cancer could develop over time.

Please ensure that you **undergo all follow-up visits** for blood tests or skin evaluations arranged by your doctor. Please have a list of all your other medicines and medical conditions available at each visit to a healthcare.

#### You should contact your doctor immediately if you experience:

Sunburn or severe skin reaction following exposure to light or sun

#### **Reporting of Side Effects**

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly by contacting The National Pharmacovigilance Centre (NPC) or the relevant competent authority. By reporting side effects, you can help provide more information on the safety of this medicine.

The National Pharmacovigilance Centre (NPC) SFDA Call Centre: 19999 | E-mail: npc.drug@sfda.gov.sa Website: https://ade.sfda.gov.sa/

#### Marketing Authorization Holder: Boston Oncology Arabia

Phone: +966 5091 95300 | E-mail: pv@bostononcology.com



This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA | Version 1.2 Date: 7.2021